Briefing
Circulating tumor DNA (ctDNA) for informing adjuvant chemotherapy (ACT) in stage II/III colorectal cancer (CRC): Interim analysis of BESPOKE CRC study.
MRD positivity was 15.6% (46/295; 6.9% stage II, 22.4% stage III) and was associated with inferior DFS (HR 20.8, 95% CI 10.0-43.4). Within the MRD-positive group, patients who received ACT had longer DFS than those observed (median 18.7 vs 6.7 months; HR 3.9, P=0.01). No ACT benefit was observed in MRD-negative patients (HR 1.1, P=0.89). Treatment was not randomized.
- n: 154 stage II and 196 stage III in this interim subset; MRD results in 295; median follow-up 24.8 months
- Assay: Signatera (tumor-informed)